Literature DB >> 24746598

Operator learning curve for transradial percutaneous coronary interventions: implications for the initiation of a transradial access program in contemporary US practice.

Israel M Barbash1, Sa'ar Minha1, Robert Gallino1, Robert Lager1, Salem Badr1, Joshua P Loh1, Hironori Kitabata1, Lakshmana K Pendyala1, Rebecca Torguson1, Lowell F Satler1, Augusto D Pichard1, Ron Waksman2.   

Abstract

OBJECTIVES: Our study aimed to assess the characteristics and outcomes of transfemoral approach (TFA) versus the initial steps of a transradial approach (TRA) program and to assess the learning curve of TRA in contemporary, US practice.
BACKGROUND: When compared to TFA, TRA has been shown to lower bleeding and vascular complications during percutaneous coronary intervention (PCI). However, use of TRA is still low. There are limited data regarding the characteristics of TRA learning curve, especially in an era with designated TRA equipment.
METHODS: Consecutive patients undergoing PCI in a single US center were divided into two cohorts according to vascular access approach: the last 250 TFA patients prior to the establishment of a TRA program and the initial 239 TRA patients following the establishment of a TRA program. Subgroup analysis of the TRA group, which was divided into five sequential case groups of 50 cases per group, was performed in order to assess TRA learning curve.
RESULTS: Overall, the baseline characteristics of TFA vs. TRA groups were comparable. Fluoroscopy time was significantly longer during TRA procedures (18±11 vs. 15±8min, respectively, p=0.002); however, contrast use was lower during TRA procedures (161±72 vs. 180±63ml, respectively, p=0.002). In-hospital outcomes were similar between the two groups, with low frequencies of mortality, myocardial infarction, and stent thrombosis. Subanalysis of TRA group for learning curve assessment showed no major differences in patient demographics among the five subgroups. In the initial cases, more PCI was performed among non-acute cases (62% in patients 1-50 vs. 8-27% in patients 51-239, p<0.001). Despite these differences, characteristics of the treated vessels were similar between groups. There was no significant change in fluoroscopy time or in the amount of iodinated contrast volume delivered. Similarly, no differences in procedural, in-hospital, and long-term outcomes were documented.
CONCLUSIONS: Adopting TRA as a default is feasible for high-volume operators without significant learning curve effects.
Copyright © 2014. Published by Elsevier Inc.

Entities:  

Keywords:  Coronary angiography; Percutaneous coronary intervention; Transfemoral; Transradial

Mesh:

Substances:

Year:  2014        PMID: 24746598     DOI: 10.1016/j.carrev.2014.03.001

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  5 in total

1.  Interventional cardiology: Transformation to transradial--safe and effective.

Authors:  Ian C Gilchrist
Journal:  Nat Rev Cardiol       Date:  2014-06-03       Impact factor: 32.419

2.  Simulator Training in Interventional Cardiology.

Authors:  Abhishek Joshi; Andrew Wragg
Journal:  Interv Cardiol       Date:  2016-05

3.  Hand dysfunction after transradial artery catheterization for coronary procedures.

Authors:  Muhammad Ayyaz Ul Haq; Muhammad Rashid; Chun Shing Kwok; Chun Wai Wong; James Nolan; Mamas A Mamas
Journal:  World J Cardiol       Date:  2017-07-26

4.  Alternative access site choice after initial radial access site failure for coronary angiography and intervention.

Authors:  Dionysios Gatzopoulos; Aggeliki Rigatou; Eleftherios Kontopodis; Ioannis Tsiafoutis; Maria Agelaki; Efstathios Lazaris; Konstantinos Kintis; Sotirios Patsilinakos; Michael Koutouzis
Journal:  J Geriatr Cardiol       Date:  2018-09-28       Impact factor: 3.327

5.  Comparison of Transfemoral Cerebral Angiography and Transradial Cerebral Angiography Following a Shift in Practice During Four Years at a Single Center in China.

Authors:  Beihai Ge; Yuhua Wei
Journal:  Med Sci Monit       Date:  2020-03-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.